Table 2.
Study subjects and responses
| ID # | Age on study (years) | Stage | Initial treatment | Arm | Number of vaccines received | Disease status |
|---|---|---|---|---|---|---|
| 098-010 | 61 | IC recurrent | P/CB × 4 then D/CB × 4 | 2 | 4 | NED |
| 098-030 | 43 | IIIB | P/CB × 6 | 2 | 4 | NED |
| 098-040 | 18 | IIIC | IV/IP P/CDDP × 6 | 2 | 4 | NED |
| 098-050 | 54 | IV | P/CB × 8 | 1 | 4 | Recurrence at 6 months, DOD at 26 months |
| 098-060 | 58 | IIIC | IV/IP P/CDDP × 6 | 2 | 4 | Recurrence at 26 months, NED in second remission |
| 098-080 | 49 | IIIB | P/CB × 8 | 1 | 4 | NED |
| 098-100 | 58 | IIIB | IP P/CB × 6 | 1 | 2 | Recurrence after V2, NED in second remission |
| 098-110 | 48 | IIIC | IV/IP P/CDDP × 6 | 1 | 4 | Recurrence at 17 months, NED in second remission |
| 098-120 | 62 | IIIC | P/CB × 6 | 2 | 1 | Recurrence after V1, AWD |
| 098-130 | 41 | IIIC | IV/IP P/CDDP × 6 | 1 | 4 | NED; unresectable meningioma detected 7/09 treated with radiation/chemo. NED |
| 098-140 | 51 | IIIC | IV/IP P/CDDP × 6 | 2 | 4 | NED |
P paclitaxel, CB carboplatin, D docetaxel, IV intravenous, IP intraperitoneal, CDDP cisplatin, NED no evidence of disease, DOD died of disease, AWD alive with disease, V vaccine